Author: toxlaw

A seized material can contain mostly S-methamphetamine within its methamphetamine fraction while containing relatively little methamphetamine overall. A historical study of nineteen samples seized in Saudi Arabia demonstrates why isomer composition and product purity must remain separate measurements.

What did the laboratory measure?

Alawi and colleagues analyzed nineteen seized samples using gas chromatography–mass spectrometry after chiral derivatization with L-TPC. The derivatization converted the enantiomers into diastereomeric products that could be separated on an achiral column. The reported chromatographic resolution was 2.16.

The specimen was seized material dissolved for chemical analysis. It was not blood, urine or a measured dose administered to a person. The findings characterize the submitted samples; they do not directly measure anyone’s exposure or impairment.

What was the total methamphetamine content?

The sum of the measured R- and S-methamphetamine concentrations ranged from 15.09 to 213.20 mg/g across the nineteen samples. Those amounts correspond to approximately 1.51%–21.32% of the sample mass, as the authors reported. The conversion is straightforward: 10 mg/g equals 1% by mass.

This is the denominator used for total product purity: the mass of methamphetamine relative to the mass of seized material. Other constituents remain outside the methamphetamine fraction. The paper identified caffeine in example chromatograms, but did not establish that caffeine accounted for every remaining component in every sample.

What does the S-isomer percentage describe?

Both enantiomers were detected in all nineteen samples, with S-methamphetamine predominant. The authors reported S fractions of 76.64%–96.19% within the methamphetamine measured. That percentage divides S-methamphetamine by the sum of S- and R-methamphetamine, not by the total mass of the seized product.

Consequently, “96% S” cannot be substituted for “96% methamphetamine purity.” Nor should the highest S fraction and highest total concentration be combined as though they necessarily came from the same sample. The ranges summarize different measurements across the series.

Why is enantiomeric excess another number?

The study calculated enantiomeric excess as 100 × (S − R)/(S + R), reporting values of 55.27%–92.38%. This expresses the imbalance between enantiomers after accounting for their combined amount. It is neither the S percentage itself nor the product’s chemical purity.

For an S-predominant mixture, the S fraction in percent equals (100 + enantiomeric excess)/2. Thus an excess of 55.27% corresponds to an S fraction of approximately 77.64%, not 55.27%. The paper’s stated minimum S percentage of 76.64% does not match that conversion from its stated minimum excess. That internal discrepancy warrants checking the sample-level data before quoting the exact lower endpoint as definitive.

Can the isomer pattern identify a manufacturing route?

The authors discussed possible synthetic histories, but the accepted manuscript contains differing interpretations: its discussion considers enrichment after a racemic synthesis, while its conclusion favors a stereospecific route and acknowledges uncertainty. The measured isomer pattern should not be presented as unique proof of one manufacturing process.

Enrichment, mixtures and other production history can complicate source inference. A matching isomer ratio alone also does not establish that two seizures came from the same batch; a differing ratio does not identify the people or location responsible.

What should a case explanation preserve?

Report total concentration in mg/g, the R/S composition and the definition of enantiomeric excess separately. Triplicate laboratory injections improve information about repeat measurement but do not turn nineteen seized samples into a representative market survey. The study supplies no human concentration–effect threshold or validated conversion from product composition to functional impairment.

Source

Alawi AI et al. Indirect chiral separation of crystal methamphetamine seized in Saudi Arabia using GC-MS. Australian Journal of Forensic Sciences. 2023;55:731–744; online 2022. doi:10.1080/00450618.2022.2079720. Historical analytical study; supplied author-accepted manuscript.

An exploratory ADAPT-2 analysis found additional improvement among participants continuing naltrexone–bupropion through twelve weeks. That finding is different from a randomized test of six weeks versus twelve weeks of treatment, and part of its comparison depended on imputed outcomes.

Why was a follow-up analysis needed?

The original ADAPT-2 trial used two six-week stages. At baseline, 109 participants were assigned to the medication combination and 294 to placebo. Eligible placebo nonresponders were then rerandomized: 114 switched to active medication and 111 remained on placebo. Participants originally receiving active medication continued it.

Li and colleagues used all 403 participants to examine changes in repeated urine-screen outcomes over the full trial. This was a secondary analysis of the same cohort, not a new trial or independent replication. The authors stated that this analysis was not preregistered and should be considered exploratory.

Which regimen was continued?

Extended-release naltrexone, 380 mg intramuscularly, was administered in weeks one, four, seven and ten. Oral extended-release bupropion was increased to 450 mg daily, with tapering after treatment. Participants supplied urine twice weekly during twelve treatment weeks, then at follow-up in weeks thirteen and sixteen.

No active-treatment group was randomly assigned to stop at week six. Consequently, continued improvement cannot by itself quantify what would have happened to the same participants if active treatment had ended then.

Why were placebo outcomes imputed?

Removing the 114 placebo nonresponders who switched treatment would change the composition of the remaining placebo group. To address this, the investigators used 1,000 imputations to simulate urine results for those participants as if they had remained on placebo during stage two.

The resulting comparison modeled all 294 original placebo participants as continuing placebo. Those counterfactual results were generated from a statistical submodel fitted to stage-two data; they were not observed specimens from people who actually stayed on placebo. Imputation addresses a design problem under assumptions, rather than creating additional measured evidence.

What improved during weeks seven to twelve?

The modeled probability of a methamphetamine-negative urine screen in the active group increased from 20.3% at week seven to 29.5% at week twelve. Table 1 and the results text report a 9.2-percentage-point increase, with a 95% confidence interval of 0.5–17.9 points and p = 0.038. The abstract prints a different lower confidence bound; the table and main results agree on 0.5.

The modeled placebo increase over the same period was 3.9 percentage points, with a 95% confidence interval of −0.3–8.1 and p = 0.072. Comparing significance within each group is not a direct test of the difference between those two stage-two changes.

What was the full-treatment comparison?

Across twelve weeks, the modeled increase was 27.1 percentage points with active medication and 11.4 with placebo. The reported difference in change was 15.8 percentage points, 95% confidence interval 4.5–27.0, p = 0.006. These are changes in modeled negative-screen probability, not the proportion continuously abstinent for twelve weeks or the original trial’s binary responder percentage.

Missed visits were treated as missing at random in the main model. Sensitivity analyses using last observation carried forward or counting missing results as positive retained a significant full-period treatment comparison. Those checks are reassuring for that comparison, but do not prove every modeling assumption or establish an optimal treatment duration.

What happened after treatment?

Neither group showed a significant change between the two post-treatment follow-up visits. With only those follow-up observations, a null change does not prove durable remission or show that stopping medication caused a plateau.

The paper supports investigating longer treatment and gradual use reduction. A prospective duration comparison and longer follow-up would be needed to establish how much additional treatment helps, for whom and for how long.

Source

Li MJ et al. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Addiction. 2024;119:1840–1845. doi:10.1111/add.16529. Exploratory secondary analysis of historical human-trial data.

A treatment-effect difference between subgroups can generate an important research question without explaining why the difference occurred. A secondary ADAPT-2 analysis compared groups of men defined by reported sexual partners and found a larger medication effect in one group. It did not establish that sexual identity biologically determines response.

Which participants were included?

Kidd and colleagues used data from the existing naltrexone–bupropion trial, rather than recruiting a new independent cohort. Of 403 participants, 277 were cisgender men. After excluding 31 with missing sexual-partner information, the analysis included 246: 151 reporting male partners, with or without female partners, and 95 reporting only female partners.

The classification used partner reports at baseline, six weeks and twelve weeks. It measured behavior within specified windows, not a comprehensive assessment of identity or lifetime orientation. Only 14 men reported both male and female partners, so that group was combined with men reporting only male partners.

What treatment and response were compared?

The active regimen combined 380 mg extended-release naltrexone by intramuscular injection every three weeks with oral extended-release bupropion targeted to 450 mg daily. The parent study used two six-week stages, with eligible placebo nonresponders rerandomized for the second stage.

Response required at least three methamphetamine-negative urine specimens among four scheduled specimens at the end of a stage. Discontinuation or at least two missing results counted as nonresponse. The analysis therefore concerned that specific endpoint, not continuous abstinence, a diagnosis of recovery or the effect of either medicine alone.

Was there a direct test of subgroup differences?

Yes. The investigators tested a contrast of treatment effects, rather than relying only on a significant result in one group and a nonsignificant result in another. After adjustment for site and recorded demographic and clinical characteristics, the reported weighted medication-versus-placebo response difference was 0.1479 in the male-partner group and 0.0227 in the female-partner-only group: approximately 14.79 and 2.27 percentage points. The subgroup contrast had p = 0.04.

That interaction result is more informative than comparing two separate p-values. It nevertheless comes from a secondary analysis with limited subgroup sample sizes and needs prospective replication. A small estimated effect in one subgroup is not proof that no individual in it can benefit.

What explanations were established?

The groups differed in recorded characteristics, including HIV status, education and ethnicity. The models adjusted for several measured variables, but subgroup membership was not randomized. The study did not experimentally isolate a biological effect of orientation, the role of sexual context, stress or any specific mechanism.

The authors had originally hypothesized a smaller medication effect in the male-partner group; the observed direction was the opposite. They also found no significant group difference in reported medication adherence or baseline moderate-to-severe depression. Those findings limit simple explanations based on presumed adherence or symptom differences.

Who cannot be represented by this result?

The analysis included no transgender men and cannot establish effects in transgender or nonbinary people. Most participants were non-Hispanic White. Men with both male and female partners could not be evaluated separately with adequate numbers, and missing partner reports excluded others.

The authors emphasized limited measures of sexual identity, compulsivity and related factors. Behavior-based categories should not be silently relabeled as fixed identities, and a sample-level result should not become an assumption about a particular person.

What does the analysis add?

It identifies a hypothesis for trials designed to examine treatment-effect heterogeneity and the factors behind it. It is a separate question from the parent trial’s overall efficacy endpoint, but uses the same participants. It neither supplies an identity-based treatment rule nor constitutes an independent replication of ADAPT-2.

Source

Kidd JD et al. Sexual Orientation Differences among Men in a Randomized Clinical Trial of Extended-Release Naltrexone and Bupropion for Methamphetamine Use Disorder. Drug and Alcohol Dependence. 2023;250:110899. doi:10.1016/j.drugalcdep.2023.110899. Historical secondary human-trial subgroup analysis.

A review can identify promising services without demonstrating that each service improves outcomes compared with an alternative. A 2021 environmental scan of methamphetamine use in pregnancy illustrates the distinction between mapping programs and establishing their effectiveness.

What did the scan collect?

Ackerman and colleagues searched academic and grey literature for human research published between January 1, 2010 and January 1, 2020. They included 80 articles and sources, identifying 463 outcome-related entries covering 210 outcomes, along with seven programs described as interventions.

Those are different counting units. Eighty publications are not necessarily 80 independent cohorts; 463 entries are not 463 participants or independent experiments. A publication could contribute to several outcome categories, and the scan included reviews as well as primary research.

What did “seven interventions” represent?

The program descriptions included multidisciplinary prenatal and postpartum services, parenting support, housing assistance, childcare, transportation and connections with substance-use care. Some programs served broader substance-use populations, including opioid-related needs, rather than methamphetamine-only populations.

The table was a catalog of identified services and descriptions. It was not a set of seven randomized trials using a common methamphetamine-specific endpoint. Listing a component such as housing support also does not isolate that component’s causal contribution from the rest of a service.

Why did the authors emphasize culturally relevant care?

The scan emerged from a partnership with a Saskatoon service supporting women with complex perinatal circumstances. The authors emphasized the lack of Indigenous-specific research and the need to consider historical, social and cultural contexts rather than treat ethnicity itself as a biological explanation for outcomes.

That evidence gap is consequential. A program can be relevant and promising without having a comparative evaluation that establishes its effect for the intended population. Conversely, absence from this scan does not prove that a community has no effective services or knowledge.

How could the search have missed programs?

The authors narrowed publication dates and search terminology during the project, partly because of time constraints. Terms related to amphetamine and some postpartum or child-focused concepts were removed. They acknowledged that including earlier literature and interventions for other substances could identify additional approaches, including earlier models of integrated care.

English-language restrictions and the selected academic and grey-literature search routes also shaped what was found. The number seven therefore describes the scan’s yield, not a verified worldwide total of available programs.

Did the outcome tallies quantify a child’s risk?

No. The scan counted articles reporting an association or no association for particular outcomes. For low birth weight, for example, 13 of 18 articles supported an association while five did not. That is a literature tally, not a 72% probability that an exposed infant will have low birth weight.

Study size, overlapping cohorts, adjustment for other exposures and differences in outcome definitions affect evidential weight. The authors noted uncertainty about confounder control in some studies and that several outcomes had only a small evidence base. Counting positive papers cannot resolve those design differences.

What would demonstrate program benefit more directly?

A stronger evaluation would specify who was eligible, who enrolled, the services actually received, an appropriate comparison, follow-up completeness and prespecified maternal and infant outcomes. It would distinguish access and acceptability from changes in health, and involve the population the service intends to support.

The scan offers a historical account of service concepts and research gaps. Its program information reflects sources available around 2021 and should not be treated as a verified current referral directory. Its evidence does not establish that methamphetamine exposure determines an individual child’s development or that any listed program has a uniform effect for every family.

Source

Ackerman M, Madampage C, Epp LJ, Gartner K, King A. An environmental scan of impacts and interventions for women with methamphetamine use in pregnancy and their children. International Journal of Gynecology & Obstetrics. 2021;155:220–238. doi:10.1002/ijgo.13851. Historical environmental scan of academic and grey literature.

A shorter medication course for neonatal opioid withdrawal is not automatically evidence of a healthier infant or a protective effect from another prenatal drug exposure. A 2023 narrative review of opioids, methamphetamine and polysubstance use explains why those interpretations require more information.

What kind of paper was this?

Wouldes and Lester reviewed maternal and infant evidence across several opioid exposures, methamphetamine and drug combinations. The literature included observational cohorts, retrospective records and selected controlled treatment studies. It was not one randomized experiment assigning pregnant people to methamphetamine or combined drug exposure.

The paper’s central concern was heterogeneity: short-acting opioids, methadone, buprenorphine and other substances do not form one interchangeable exposure category. Much of the better-characterized opioid evidence involved treatment medications, whereas some other combinations remained poorly studied.

Why does the withdrawal endpoint need definition?

Neonatal opioid withdrawal syndrome concerns a pattern of signs after opioid exposure. Treatment duration reflects both an infant’s course and clinical decisions: how signs were assessed, when medication was started, what protocol was used and when treatment was stopped.

A length-of-treatment result is therefore not identical to a direct measure of overall neurodevelopment, organ injury or subsequent health. Hospital length of stay is another distinct endpoint. Neither should substitute silently for the other.

What did the mixed-exposure evidence show?

The review summarized one report involving 175 opioid-exposed infants: 33 with opioids alone and 142 with additional substances. Overall treatment duration and hospital stay were similar between the opioid-only and polysubstance groups. Subgroup observations suggested that opioid duration of action and combinations of short- and long-acting opioids mattered.

The review also described an association between stimulant co-exposure and shorter treatment with less adjunctive medication. It cautioned that this could reflect the properties of short-acting opioids rather than a stimulant effect. A broad stimulant category also cannot be assumed to establish a methamphetamine-specific result.

Could co-exposure change the signs being scored?

Possibly. The authors discussed how different drug combinations could intensify, suppress or alter the signs used to recognize withdrawal. They described lower arousal and less excitability in selected methamphetamine-exposed newborn assessments, a pattern different from typical opioid-withdrawal presentations.

That is a reason to investigate assessment validity in mixed exposures, not proof that methamphetamine masks withdrawal in every co-exposed infant. The review did not supply a validated correction factor that converts a score into the severity that would have occurred without methamphetamine.

Does absence of typical opioid withdrawal exclude methamphetamine effects?

No. A scale focused on opioid withdrawal is not a comprehensive test for every possible effect of prenatal methamphetamine exposure. The review noted that methamphetamine-exposed infants in the IDEAL literature did not show the same typical withdrawal pattern and did not require pharmacological withdrawal treatment in the reported comparison.

Those observations do not prove that all neonatal outcomes were normal, or that every sign in an exposed infant is drug-caused. Growth, feeding, neurobehavior and later development require their own measurements and comparisons.

What information matters in an individual review?

The relevant record includes the specific opioid and other exposures, timing, ascertainment method, gestational age, clinical course, assessment instrument and treatment protocol. A binary “polysubstance” label conceals meaningful variation. Other prenatal exposures and maternal health and social conditions can also complicate observational comparisons.

The defensible interpretation is that shorter treatment may have several explanations. This review does not establish prenatal methamphetamine as protective, provide a treatment algorithm or permit impairment conclusions from a newborn or maternal toxicology result. It identifies a need for better-defined co-exposure studies and assessment methods.

Source

Wouldes TA, Lester BM. Opioid, methamphetamine, and polysubstance use: perinatal outcomes for the mother and infant. Frontiers in Pediatrics. 2023;11:1305508. doi:10.3389/fped.2023.1305508. Historical narrative review; individual studies discussed here are secondary summaries.

When a rat study reports methamphetamine “craving” or “relapse,” the measured behavior may be lever pressing in a chamber where no drug is delivered. That model can be scientifically useful while still requiring careful translation into human language.

What did the review examine?

Elhadi, Daiwile and Cadet reviewed molecular and biochemical consequences of methamphetamine self-administration in rodents, particularly transcriptional findings in the dorsal striatum. The 2023 paper synthesized several protocols and earlier experiments rather than reporting one new clinical trial.

The review describes rats earning intravenous methamphetamine infusions, including protocols using 0.1 mg/kg per infusion during nine- to fifteen-hour access sessions. The amount per infusion is not the total daily dose. Session length, number of earned infusions and days of access all determine cumulative exposure.

Why distinguish self-administration from investigator dosing?

In self-administration, a learned action controls drug delivery. In a noncontingent dosing experiment, the investigator determines delivery independently of that action. These arrangements differ in learning, cues, timing and control as well as potentially in total exposure.

A molecular change following one arrangement should not automatically be assigned to every form of methamphetamine exposure. The review specifically emphasizes that different schedules can produce different transcriptional consequences.

How was drug seeking measured during abstinence?

After training, investigators could withhold access to methamphetamine and later test responding to drug-associated cues. More lever pressing at a later withdrawal time, despite the absence of drug delivery, is commonly termed incubation of drug craving.

That operational measure does not directly report an animal’s subjective experience, nor does it always represent renewed drug consumption. “Drug seeking” and “drug taking” must remain separate when the test supplies no drug. Forced abstinence imposed by the experimenter is also different from a person’s voluntary choice, access barriers or treatment course.

What does punishment resistance measure?

The review describes introducing intermittent foot shocks after approximately four weeks of self-administration training. Rats that continued lever pressing despite the contingency were classified as punishment-resistant; those suppressing responding were classified as punishment-sensitive.

These labels describe behavior under the study’s specific conditions. They are not judgments about character and do not measure a person’s capacity to understand consequences. Differences in the laboratory groups can generate hypotheses about compulsive drug taking, but they cannot establish why a particular human continued use despite adverse circumstances.

How were the molecular findings linked to behavior?

Brain tissue was collected at differing intervals, including hours, days and weeks after self-administration. Investigators examined gene expression, epigenetic regulation and other biochemical measures. The review emphasized genes and pathways involving transcription, potassium channels and inflammatory signaling.

A difference in messenger RNA abundance is not automatically a change in protein activity, and an associated molecular signature is not necessarily the cause of the behavioral difference. Tissue collected after a behavioral test may reflect exposure, withdrawal, learning, testing or their combination. Timing is consequently part of the biological interpretation.

Does this validate a human relapse biomarker?

No. The review explicitly identifies unresolved questions about which gene-expression changes produce behavioral effects and calls for broader investigation across brain regions and human tissue. A promising animal target is not a validated clinical assay or an established treatment.

The model’s value is experimental control and the ability to test mechanisms. Its limits include the particular species, access schedule, laboratory contingencies, sampled brain region and observation window. Those details should accompany any claim about what animal methamphetamine research means for an individual person.

Source

Elhadi K, Daiwile AP, Cadet JL. Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional, and biochemical consequences in the rat brain. Neuroscience & Biobehavioral Reviews. 2023;155:105440. doi:10.1016/j.neubiorev.2023.105440. Historical review of preclinical animal evidence.

Methamphetamine detected in a river, accumulated in a fish brain and ingested by a person would represent three different exposure questions. A 2024 review of illicit drugs in surface waters helps explain why those steps cannot be collapsed into a claim of human intoxication.

What did the paper actually contribute?

Falfushynska and colleagues reviewed environmental occurrence and fish studies involving multiple drugs. This was a review, not a new experiment exposing people or testing a market basket of edible fish. Its methamphetamine discussion combined laboratory waterborne exposures, tissue measurements and behavioral observations from different fish species.

The underlying experiments differed in concentration, duration, life stage, mixtures and endpoints. They cannot be treated as one standardized exposure study or pooled into an unreported human dose estimate.

Why must water and tissue units stay separate?

Water concentrations were commonly expressed in ng/L or µg/L, while tissue concentrations used mass per tissue mass, such as ng/g wet weight. A water concentration describes the external medium. It does not directly give the amount absorbed by a fish or the amount a person would consume in a meal.

As one example, the review summarizes a zebrafish experiment with a methamphetamine–ketamine mixture at nominal concentrations of 0.01, 1 and 100 µg/L for 14 days, followed by seven days in clean water. At the highest exposure, it reports mean methamphetamine concentrations reaching approximately 425 ng/g wet weight in brain. That is a specific tissue measurement under a mixture-exposure protocol, not a methamphetamine concentration in ordinary edible muscle across rivers.

Does brain accumulation establish dietary risk?

No. A dietary calculation would require concentrations in the tissue actually eaten, the amount consumed, preparation effects, oral absorption and an appropriate human dose–response comparison. The review did not supply a validated calculation of that kind for methamphetamine.

Bioconcentration also should not be confused with biomagnification. Accumulation from water into an organism does not by itself demonstrate progressively greater concentrations at successive levels of a food chain. Nor does a tissue-to-water relationship establish that concentrations increase without limit over time; uptake and elimination both matter.

What do the fish behavior findings mean?

The review describes altered movement and drug-preference behavior in selected experiments, including brown trout exposed to 1 µg/L methamphetamine. Such findings can be relevant to ecological function because feeding, movement and predator avoidance matter to fish survival.

However, an animal preference assay is an operational behavioral measure. It is not a human diagnostic assessment of addiction, and an altered swimming measure is not a human impairment test. The review’s broad language about addiction-like effects should remain attached to the species and experimental protocol.

Why are mixtures and metabolites important?

A combined methamphetamine–ketamine experiment cannot automatically attribute every outcome to methamphetamine alone. Methamphetamine and its metabolite amphetamine can also have different distributions across tissues. A result for one analyte should not be relabeled as a concentration of the other, and a brain measurement should not stand in for a whole-fish measurement.

The review is useful for identifying possible ecological hazards and research gaps. Its heterogeneous studies do not define a single concentration at which every fish species is affected, and they do not demonstrate that all affected fish populations decline.

What is the appropriate conclusion?

Environmental methamphetamine deserves measurement and carefully designed ecotoxicology research. Evidence of occurrence or laboratory effects does not, on its own, establish human dietary injury, a safe consumption limit or intoxication in an individual. Those conclusions require additional exposure and outcome evidence that this review was not designed to provide.

Source

Falfushynska H et al. Illicit Drugs in Surface Waters: How to Get Fish off the Addictive Hook. Pharmaceuticals. 2024;17:537. doi:10.3390/ph17040537. Review of environmental observations and animal experiments; underlying experiments are summarized here as review evidence.

A treatment can improve outcomes while it is delivered even when its added benefit is uncertain after it stops. A 2008 review of cognitive and behavioral therapies for methamphetamine dependence makes that timing distinction particularly clear for contingency management.

What kind of evidence was reviewed?

Lee and Rawson examined randomized cognitive and behavioral intervention studies available at the time. The review included cognitive behavioral therapy, relapse prevention, motivational approaches and contingency management. It was a historical literature review, not a new trial and not an assessment of the complete evidence available today.

The authors emphasized that much stimulant-treatment research involved cocaine, or combined cocaine and methamphetamine samples without separate analyses. Evidence labeled “stimulant treatment” therefore did not always establish a methamphetamine-specific effect.

What did contingency management mean?

Contingency management delivered a reward when a defined behavior occurred, such as submission of a drug-negative urine specimen. Different studies used vouchers, prize drawings and different schedules or maximum reward values. Attendance incentives and abstinence incentives are not identical interventions.

The practical comparator mattered too. Adding incentives to usual care asks whether the incentives improve outcomes beyond that care. Comparing incentives against a separate counseling program asks a different question. Combining these designs into one generic “treatment versus nothing” claim would misrepresent the evidence.

What happened during treatment?

The review summarized a methamphetamine-specific trial of 113 participants comparing usual care with usual care plus contingency management over 12 weeks. The incentive group provided more methamphetamine-free urine specimens and achieved longer abstinence, but retention did not differ between groups. Improvement in one endpoint did not establish improvement in every endpoint.

Another comparison involved 16 weeks of contingency management, cognitive behavioral therapy or both in a mixed-stimulant sample. Contingency management improved retention and stimulant-use outcomes during treatment, but the drug groups were not separated. That result should not be presented as a precise estimate for methamphetamine alone.

What happened after treatment?

In several comparisons, between-group differences seen during treatment were no longer apparent at follow-up. Other studies did not provide post-treatment follow-up at all. These are different evidence states: an observed nonsignificant later comparison is not the same as an unmeasured later outcome.

Neither finding proves that participants lost all improvement. If all groups improve, the added advantage of one intervention can narrow while people retain some benefit. Conversely, a significant during-treatment effect cannot be assumed to persist indefinitely when follow-up is absent.

Why does the control condition matter?

The review described brief-intervention studies in which comparison participants received a self-help booklet based on cognitive behavioral principles. Assessment and repeated follow-up could also influence behavior. An active comparison can reduce the contrast between groups without showing that neither approach helps.

Similarly, several papers could arise from one underlying trial. Multiple publications exploring mood, use and subgroup outcomes do not become independent replications merely because they have different titles.

How should this historical review be used?

It supports a disciplined reading of treatment duration, comparator and follow-up. The review identified promising during-treatment findings and uncertainty about longevity, while also documenting null results and gaps. It does not supply a current prescribing or service guideline, an optimal incentive amount or a prediction for one person.

For research interpretation, report the behavior rewarded, the drug-specific specimen endpoint, the treatment period and the actual follow-up separately. A negative urine specimen remains an outcome measurement within the trial; it is not a general certification of functional recovery or absence of impairment at another time.

Source

Lee NK, Rawson RA. A systematic review of cognitive and/or behavioural therapies for methamphetamine dependence. Drug and Alcohol Review. 2008;27:309–317. doi:10.1080/09595230801919494. Historical review of controlled human studies.

Changes in methamphetamine use, treatment admissions and overdose mortality can diverge. Comparing them can identify important questions about disparities, but separate surveillance systems do not track a single set of people from use through treatment to death.

Which three systems were compared?

Shearer and colleagues analyzed historical United States adult data for trends through 2019. The National Survey on Drug Use and Health supplied self-reported past-30-day use; the Treatment Episode Data Set–Admissions supplied treatment episodes; and CDC multiple-cause-of-death records supplied overdose deaths.

The analysis used rolling three-year averages. A rate labeled 2010 therefore included 2008–2010 information rather than only events or interviews from calendar year 2010. Smoothing helps stabilize sparse estimates, but adjacent annual points share data and should not be read as independent yearly snapshots.

Were the geographic populations identical?

No. Treatment and mortality analyses excluded the District of Columbia and eight states because treatment data were missing in one or more years. The public survey data did not provide corresponding state identifiers for the same exclusion. Sensitivity analyses examined the effect of the geographic restrictions, but the main systems still differed in coverage.

Treatment records counted admissions, so one person could appear more than once. The survey estimated people reporting use, while death records counted deaths. Dividing admission rates by use rates would not produce a verified percentage of users who received treatment.

What did the methamphetamine trends show?

Between 2010 and 2019, estimated use increased significantly in the authors’ White and Hispanic groups: 133% with a 95% confidence interval of 77%–188%, and 247% with an interval of 58%–435%, respectively. Upward use trends in the other reported racial and ethnic groups were not statistically significant. Nonsignificance should remain visible rather than being rewritten as no increase.

Treatment admissions and overdose deaths showed different patterns. The authors reported a 1,115% relative increase in the methamphetamine-labeled overdose rate among Black adults and 744% among American Indian adults. Relative increases depend strongly on the starting rate. In 2019, the reported death rates were 13.3 per 100,000 in the American Indian group and 5.5 per 100,000 in the White group; these absolute rates answer a different question from the percentage changes.

Was every “methamphetamine” death chemically specific?

No. The mortality analysis used ICD-10 T43.6, psychostimulants, which the article referred to as methamphetamine. That category is not exclusive to methamphetamine. The indicators were also nonexclusive: a death or admission could involve more than one substance. The figures do not establish methamphetamine-alone mortality.

Survey reports, admission classifications and death-certificate coding each have their own ascertainment limitations. Combining their graphs does not remove those limitations or create individual-level exposure verification.

How should racial and ethnic differences be interpreted?

The sources collected group information differently: survey self-identification, information recorded at admission, and death-certificate information often supplied by next of kin or observation. The harmonization also excluded some multiracial and missing-data categories.

These are surveillance categories, not evidence that race biologically determines methamphetamine toxicity. Differences can reflect social conditions, access to treatment, drug supply, other exposures and recording practices. The study did not isolate a single mechanism for the disparities.

What conclusions remain useful?

Divergent trends can highlight where further investigation and better service data are needed. They cannot establish an individual’s probability of dying after use, prove that treatment caused or prevented a death, or determine impairment. The value of triangulation is the broader view it provides while preserving the distinct populations and measurements behind each line.

Source

Shearer RD et al. Racial and ethnic differences in heroin, methamphetamine, and cocaine use, treatment, and mortality trends in three national data sources—United States, 2010–2019. Medical Care. 2024;62:151–160. doi:10.1097/MLR.0000000000001969. Historical observational surveillance analysis.

Wastewater measurements can reveal a changing chemical signal without establishing why it changed. A study of two cities in southwest China attributed declining methamphetamine estimates largely to anti-drug measures, but its design supports a narrower conclusion about the sampled periods.

How much of the year was actually sampled?

Tao, An and Wang studied eight wastewater treatment plants, four in each anonymized city. They conducted campaigns in March, June, September and December 2019. Each campaign collected two samples per plant: one weekday and one weekend sample.

That schedule provided eight sampling occasions per plant across the year, not continuous daily surveillance for four months or twelve months. The article appeared online in October 2024 and in a 2025 journal volume; the measurements remain historical 2019 evidence.

What decline did the investigators estimate?

After chemical analysis and back-calculation, the authors reported that December population-weighted methamphetamine consumption estimates were approximately 47% lower than March in City 1 and 44% lower in City 2. The mean across the four sampled periods was 188.6 mg per 1,000 inhabitants per day in City 1 and 57.0 in City 2.

Those units describe modeled consumption mass normalized to population and time. They do not describe water concentrations, percentages of residents using methamphetamine or numbers of diagnosed disorders. The percentage declines compare the selected campaigns and do not measure every intervening day.

What assumptions entered the population estimate?

Methamphetamine concentrations were converted using a correction factor of 2.44, derived from published excretion information. Population estimation used cotinine as a biomarker, with an assumed nicotine consumption of 1.5 mg per inhabitant per day and a cotinine correction factor of 2.85.

Cotinine normalization can address some changing catchment-population issues, but it introduces its own assumptions about nicotine consumption and excretion. If those assumptions vary between sites or seasons, normalized drug estimates may shift even without a proportional change in methamphetamine consumption. Chemical measurement and population modeling should not be collapsed into a single assumption-free observation.

Does the weekday comparison identify regular users?

The study found no significant weekday-versus-weekend methamphetamine difference in either city: p = 0.707 and p = 0.065. The authors interpreted the pattern as suggesting regular rather than recreational use.

That is a hypothesis about aggregate behavior. A nonsignificant difference from a sparse sampling design is not an equivalence test, and wastewater cannot identify which individuals used regularly. Differences in excretion timing, catchment composition and sampling variation can also affect weekday comparisons.

What would be needed for a policy-effect claim?

The reported design did not randomize enforcement or prevention measures, identify an untreated comparison city for a specified intervention, or provide a sufficiently dense pre-intervention trend to establish a policy counterfactual. Observing lower estimates after time has passed does not exclude seasonality, supply changes, population shifts or other simultaneous influences.

The paper discussed anti-drug activities as a likely explanation. That interpretation should remain attributed to the authors, rather than presented as a measured causal effect. A stronger policy evaluation would define the intervention, its timing, comparison conditions and alternative explanations in advance.

What is the defensible use of this study?

It documents spatial differences and a lower modeled methamphetamine signal in the later sampled campaigns. It can guide hypotheses and future surveillance design. It cannot establish that a particular policy caused the decline, identify an individual’s consumption or determine impairment from a community wastewater measurement.

Source

Tao H, An Q, Wang H. Short-Term Trends and Site Differences of Methamphetamine and Ketamine Consumption in Two Cities by Wastewater Analysis. Polish Journal of Environmental Studies. 2025;34:5271–5279; online 2024. doi:10.15244/pjoes/190788. Historical environmental observational evidence.